Clinical trial
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT03653507 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 28, 2018
- Completion date
- March 31, 2027
- Enrollment
- 507 (actual)
- Sites
- 165
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced unresectable gastric adenocarcinoma or cancer, locally advanced unresectable gastroesophageal junction (gej) adenocarcinoma or cancer, metastatic gastric adenocarcinoma or cancer, metastatic gastroesophageal junction (gej) adenocarcinoma